Table 1 Clinicopathologic characteristics of study participants
| Â | Overalla | Response to platinum-based therapy | ||
|---|---|---|---|---|
Resistant | Sensitive | P-valueb | ||
N | 79 | 19 | 59 | Â |
Age at diagnosis, mean (SD) | 61.4 (11.1) | 62.0 (12.4) | 60.9 (10.6) | 0.71 |
Stage, n (%) | ||||
 I,II | 8 (10) | 1 (5) | 7 (12) | 0.41 |
 III,IV | 71 (90) | 18 (95) | 52 (88) |  |
Debulking status, n (%) | ||||
 Suboptimal (Residual disease > 1 cm) | 18 (24) | 5 (26) | 12 (21) | 0.66 |
 Optimal (NED or residual disease < 1 cm) | 58 (76) | 14 (74) | 44 (79) |  |
Lymphovascular Invasion, n (%) | ||||
 Yes | 62 (78) | 15 (79) | 46 (78) | 0.93 |
 No | 17 (22) | 4 (21) | 13 (22) |  |
Cystic Component, n (%) | ||||
 Yes | 54 (69) | 13 (72) | 40 (68) | 0.72 |
 No | 24 (31) | 5 (28) | 19 (32) |  |
STIC, n (%) | ||||
 Yes | 20 (28) | 4 (22) | 16 (31) | 0.49 |
 No | 51 (72) | 14 (78) | 36 (69) |  |
TIL, n (%) | ||||
 Yes | 32 (41) | 10 (56) | 22 (37) | 0.17 |
 No | 46 (59) | 8 (44) | 37 (63) |  |
Vital Status, n (%) | ||||
 Alive | 24 (31) | 3 (16) | 21 (36) | 0.10 |
 Died | 54 (69) | 16 (84) | 38 (64) |  |
Months of follow-up, mean (SD) | 60 (33) | 36 (32) | 58 (31) | 0.008 |